Introduction
Apoptosis has been shown to be inducible in both normal as well as diseased tissues by a variety of stimuli (Fraser and Evans, 1996; Henkart, 1996) and loss of either the apoptotic stimulus or responsiveness to these stimuli may lead to chronic pathologic conditions including autoimmunity and cancer. Several biological, physical and chemical mediators have been shown to contribute to the apoptotic signal. These include environmental stress induced through DNA damaging drugs (Dubrez et al., 1996; Lumelsky and Schwartz, 1996) , radiation (Chen et al., 1996a; Santana et al., 1996) , oxidation (Goossens et al., 1995; Wong et al., 1989) and growth factor withdrawal (Stefanis et al., 1996; Gagliardini et al., 1994) . In addition, cytokines, such as TNF and Fas ligand, bind speci®c cell surface receptors and activate a cell death program (Nagata and Golstein, 1995; Cleveland and Ihle, 1995) . TNF receptor, which shares functional but limited structural homology with Fas, induces apoptosis by receptor clustering and stimulation of a cascade of events including activation of speci®c proteases, termed caspases, which cleave select substrates at aspartic acid residues (Fraser and Evans, 1996; Hsu et al., 1995; Boldin et al., 1996; Muzio et al., 1996; and inhibition of these proteases suppresses TNF or Fas induced apoptosis (Fraser and Evans, 1996; Enari et al., 1996; Tewari and Dixit, 1995) . In addition, there is evidence of a role for intracellular calcium and its redistribution in the apoptotic process which may contribute to the onset of cell death by activation of a distinct group of proteases with calcium sensitive regulatory domains (Dowd, 1995; Nicotera et al., 1992) . Thus, several proteolytic activities are likely to play a role in apoptosis.
Recent studies of cellular apoptotic sensitivity suggest that growth factors which transduce their proliferative signals through activation of a tyrosine kinase cascade can modulate cellular sensitivity to a variety of apoptotic signals (Wu et al., 1996; Gardner and Johnson, 1996; Tilly et al., 1992; Garcia-Lloret, 1996) . These studies parallel those previously described for the protective eects of speci®c growth factors which activate receptor tyrosine kinases and inhibit TNF-induced apoptosis (Sugarman et al., 1987) . Overexpression of speci®c protein tyrosine kinases has also been correlated with resistance to the cell killing eects of TNF through an unknown mechanism (Hudziak et al., 1988; Shephard and Lewis, 1988; Nishikawa et al., 1994; Aggarwal et al., 1994) . Inhibitors of tyrosine kinases and phosphatases can modulate apoptosis and tyrosine phosphorylation has been shown to be modulated prior to and during apoptosis (Wu et al., 1995; Schieven et al., 1995; Liles et al., 1996; Migita et al., 1995; Youse® et al., 1994; Eischen et al., 1994) . Recent studies have also shown that inhibitors of apoptosis can induce tyrosine phosphorylation of speci®c proteins and a protein tyrosine phosphatase expressed in hematopoetic and other cell types (SHPTP1, HCP or PTPase1C) has been shown to eect Fas-mediated apoptosis in some tumor cells (Su et al., 1995) . Therefore, tyrosine phosphorylation may play a regulatory role in the induction and execution of cell death. Several PTPs have been described which may participate in cell death, growth suppression and modulation or activation of speci®c signal transduction cascades (Tonks and Neel, 1996; Byon et al., 1997) . However, the extent of their participation and the cellular role of several of these proteins remains unclear. One important example is that of PTP1B, which was initially described as a 37 kDa protein with tyrosine speci®c protein phosphatase activity (Tonks et al., 1988) . Subsequent studies demonstrate that this puri®ed protein represented a truncated form of a 50 kDa enzyme which was later shown to be associated with the endoplasmic reticulum (ER) (and other membranous organelles) through hydrophobic interaction of its C-terminus with the cytoplasmic face of the ER membrane (Frangioni et al., 1992) . Studies have shown that PTP1B is a cellular substrate of several protein kinases involved in cell cycle regulation, stress responses and signal transduction including recent reports of its tyrosine phosphorylation by insulin and other growth factors which may regulate PTP1B enzymatic activity (Flint et al., 1993; Shifrin et al., 1997; Bandyopadhyay et al., 1997; Liu and Cherno, 1997) . Other studies have shown that limited and speci®c proteolysis of PTP1B stimulates its enzymatic activity, possibly through disruption of its membrane association (Frangioni et al., 1992 (Frangioni et al., , 1993 . Studies have shown that the extent or site of proteolysis of PTP1B may control its access to distinct cellular substrates. For example, cleavage of its C-terminus by calpain activation, correlates with the appearance of a 42 kDa PTP1B-like protein, stimulation of PTP1B activity and release from the ER. More recent studies suggest that truncation of PTP1B to a 37 kDa protein exposes a proline-rich region of PTP1B which permits its interaction with substrates expressing SH3 domains . Therefore, as previously proposed, speci®c proteolysis and localization of PTP1B are likely to play important roles in determining both PTP1B activity and accessibility to substrates (Lammers et al., 1993) .
In this report the eects of TNF on the tyrosine phosphorylation state of EGFr in ME-180 cells expressing intrinsic sensitivity or resistance to TNFinduced apoptosis were examined. We report that prior to the onset of apoptosis, TNF induced suppression of EGFr tyrosine phosphorylation in TNF-sensitive cells but had only limited eects on receptor tyrosine phosphorylation in TNF resistant cells. Biochemical evidence for activation of a membrane-associated PTP by TNF with characteristics similar to that of PTP1B was suggested by in vitro studies. Distinctions in expression and activity of PTP1B-related proteins between cell lines expressing apoptotic sensitivity and resistance to TNF were also observed and speci®c cellular translocation of PTP1B-related proteins was measurable in TNF treated apoptotically sensitive but not resistant cells. Together, these ®ndings provide ®rst evidence for the possible involvement PTP1B and related proteins in TNF action and apoptotic sensitivity.
Results
We have previously isolated and characterized clonal variant cell lines from the ME-180 cervical carcinoma cell population which expressed intrinsic sensitivity or resistance to TNF-mediated apoptosis (Nishikawa et al., 1994; Donato et al., 1993; Perez and Donato, 1996) . The initial characterization of these cell lines suggested that overexpression of EGFr was associated with loss of TNF apoptotic sensitivity in a manner similar to that previously described for overexpression of the HER2/Neu oncoprotein (Hudziak et al., 1988; Shephard and Lewis, 1988; Nishikawa et al., 1994; Perez and Donato, 1996) . Apoptosis, as demonstrated by the onset of DNA fragmentation, was measurable in Sen cells beginning 16 h after treatment with 470% of the population committed to apoptosis 24 h after TNF addition ( Figure 1A) . Cleavage of the caspase substrate poly-ADP-ribose polymerase (PARP) was also used as a marker of apoptosis in these cells. As shown in Figure 1B , TNF treatment resulted in cleavage of PARP in Sen but not Res cells, providing biochemical evidence for dierential activation of apoptosis in these cell lines. Thus, as shown here and previously described, TNF was unable to induce apoptosis in Res cells (Nishikawa et al., 1994; Donato et al., 1993; Perez and Donato, 1996) .
To determine whether TNF receptor was able to activate downstream signaling pathways in apoptotically responsive and resistant cells, nuclear translocation of NF-kB was investigated in TNF treated cells. As shown in Figure 1C , TNF was able to activate NFkB in both Sen and Res cells when measured by electrophoretic mobility shift assays with nuclear protein extracts. Nuclear protein complexes with the 32 P-labeled NF-kB consensus binding sequence (Nabel and Baltimore, 1987) increased following TNF treatment in either cell line and this association was reduced in the presence of excess unlabeled oligomer. Although some distinctions are evident in the nuclear level of NF-kB after 30 min of treatment in this experiment, this eect was not consistently observed since subsequent and additional studies were unable to resolve distinctions between cell lines. Importantly, TNF-mediated NF-kB activation in these cell lines suggests expression of a functional TNF receptor in both Sen and Res cells (Hsu et al., 1995; .
Activation of TNF receptor has also been shown to stimulate stress-activated protein kinases such as JNK and p38 . Analysis of JNK expression in these response variant cells demonstrated lower JNK levels in Res cells ( Figure 1D ). However, TNF was able to transiently stimulate JNK activation in both cell types with only minimally measurable distinctions in the fold-stimulation of activity. Therefore, TNF activates receptor signaling cascades in both ME-180 cell variants, suggesting possible distinctions or defects in other downstream signaling processes which eect intrinsic TNF apoptotic sensitivity (Hsu et al., 1995; Boldin et al., 1996) .
Overexpression or activation of EGFr has previously been shown to be associated with apoptotic resistance to TNF (Garcia-Lloret et al., 1996; Sugarman et al., 1987; Donato et al., 1993; Perez and Donato, 1996) . To determine whether TNF aected EGFr tyrosine phosphorylation in ME-180 cells, Sen and Res cells were treated with TNF and EGFr tyrosine phosphorylation was examined by immunoprecipitation and immunoblotting. As shown in Figure 2 , TNF caused a reduction in the tyrosine phosphorylation state of EGFr without aecting EGFr protein levels. Importantly, greater suppression of EGFr tyrosine phosphorylation was measurable in TNF treated Sen versus Res cells in two independent experiments. These studies suggested that TNF mediated a reduction in EGFr tyrosine phosphorylation and there may be distinctions in TNF-induced suppression of EGFr tyrosine phosphorylation in cells expressing apoptotic sensitivity or resistance to TNF.
The eect of TNF on EGFr tyrosine phosphorylation suggested the possible involvement of an inhibitor of EGFr tyrosine autokinase or other EGFr-directed tyrosine kinase activity, or conversely, TNF-mediated activation or induction of PTP activity. To distinguish between these possibilities, studies were initiated on subcellular fractions to determine whether TNF was able to mediate similar eects on EGFr tyrosine phosphorylation in vitro. The membrane fraction from ME-180 Sen cells was treated with a broad range of TNF (and EGF) concentrations in vitro and EGFr tyrosine phosphorylation was assessed by SDS ± PAGE and immunoblotting. Preliminary studies suggested that when combined with ferrous or ferric ion (which have previously been shown to participate in the propagation of oxygen radicals and alter TNF cellular responses; Korsmeyer, 1995; Warren et al., 1993) . TNF was able to induce speci®c changes in membrane protein phosphorylation without eecting EGFr 32 P]ATP. Phosphorylation of GST-jun was determined by SDS ± PAGE followed by autoradiography and quantitated by phosphorimager (bottom). The 30 and 60 min fold-activation over 0 min control for Sen and Res cells are 9.6 and 3.1 versus 9.0 and 0.8 respectively. Similar results were obtained in two additional experiments protein levels (data not shown). As shown in Figure 3 , TNF, at concentrations 410 nM, maximally suppressed EGFr tyrosine phosphorylation (460% of control). EGF incubation (at 10 ± 100 nM) under these conditions stimulated receptor tyrosine phosphorylation and demonstrated that EGFr retained its binding and nominal enzymatic activity after preparation of the membrane fraction. Thus, the membrane fraction retained a TNF-responsive activity capable of suppressing EGFr tyrosine phosphorylation.
To distinguish between inhibition of phosphorylation and activation of a PTP activity by TNF, a peptide mimicking an autophosphorylation site on EGFr (Y992) was synthesized, tyrosine phosphorylated with [ Sodium vanadate has been shown to be potent inhibitor of PTP activity (Tonks et al., 1988) and studies were initiated to determine whether TNFmediated suppression of EGFr tyrosine phosphory- (1 mM) for 30 min at 48C. After heating with SDS-sample buer, proteins were resolved by SDS ± PAGE and immunoblotted for phosphotyrosine. The eect of treatment on EGFr phosphotyrosine was determined by densitometry and compared to control levels. TNF caused 65, 67 and 44% inhibition of EGFr tyrosine phosphorylation at concentrations of 1000, 100 and 10 nM, respectively. EGF stimulated greater than twofold increased EGFr tyrosine phosphorylation (258% at 100 nM and 212% at 10 nM) Figure 4 Eect of treatment on the dephosphorylation of Y992 phosphopeptide by Sen cell membranes. Radiolabeled phosphopeptide (Y992) was incubated with the membrane fraction derived from Sen cells in the presence of cofactors [10 mM MnCl 2 0.5 mM FeSO 4 ] and buer alone (Control), TNF (500 nM), EGF (500 nM) or their combination (TNF and EGF) for 30 min (48C). The reactions were quenched by acidi®cation, membranes repelleted and supernatant aliquots were resolved into free 32 P and 32 Pphosphopeptide by reverse-phase HPLC. Fractions were analysed for radioactivity and CPM representing free 32 P (fractions 6 ± 9) and 32 P-phosphopeptide (fractions 56 ± 59) were compared between treatment groups. A typical HPLC separation is shown (top). The quantitated eects of treatment on free 32 P are also shown (bottom) which represent the average+s.e.m. of three determinations lated could be blocked with sodium vanadate. As shown in Figure 5 , TNF suppressed EGFr tyrosine phosphorylation (by 60%) when assessed by incorporation of 32 P into EGFr or phosphotyrosine immunoblotting. The presence of vanadate (1 mM) in the incubation mixture protected EGFr from TNFmediated suppression, providing additional evidence for the involvement of a vanadate-sensitive PTP in TNF-stimulated EGFr dephosphorylation in vitro.
PTP1B has been implicated in the control and modulation of several tyrosine phosphorylation-controlled signaling pathways (Frangioni et al., 1993; Kenner et al., 1996; Wiener et al., 1994; Zhai et al., 1993; Woodford-Thomas et al., 1992) and recent studies suggest a speci®c role for PTP1B modulation of EGFr phosphotyrosine levels through direct association of these proteins in a phosphotyrosinedependent fashion (Flint et al., 1997) . Since initial studies suggested membrane-association of a TNFstimulated PTP with properties similar to that of PTP1B, its potential role in dephosphorylation of EGFr was investigated. To determine whether EGFmediated tyrosine phosphorylation of EGFr induced an association between EGFr and PTP1B, membrane preparations were incubated with [ 32 P]ATP and cytokines and EGFr was immunoprecipitated with antibodies directed against EGFr or PTP1B. As shown in Figure 6a , immunoprecipitation of EGFr from treated membrane fractions demonstrated similar eects of TNF and EGF on receptor phosphorylation as those described above (Figure 3 ). Activation of EGFr (by incubation with EGF) increased its tyrosine autophosphorylation (as previously described, Donato et al., 1992) and its apparent coprecipitated with PTP1B. Treatment with both TNF and EGF reduced both the level of EGFr tyrosine phosphorylation and Membranes isolated from Sen cells were treated with TNF (500 nM), EGF (500 nM) or a combination of both factors and incubated in the presence of [ 32 P]ATP. The reactions were quenched and divided into equal aliquots which were subjected to immunoprecipitation with anti-EGFr (left) or anti-PTP1B (FG6-1G; center). After washing, immune-complexes were resolved by SDS ± PAGE and phosphoproteins detected by autoradiography (top). The same autoradiographic exposure (20 min) was used for both Figures. The electrophoretic migration of the 170 kDa EGFr phosphoprotein is shown. Gel slices representing the 170 kDa phosphoprotein in PTP1B immunoprecipitates from EGF or EGF+TNF treated samples were excised, acid hydrolyzed and subjected to thin-layer cellulose electrophoretic separation for phosphoamino acid analysis of 32 P-labeled protein (right). The relative migration of phosphoamino standards from the origin (*) is shown (arrows). (B) Aliquots of the Sen cell membrane fraction (50 mg of protein) were treated with EGF (500 nM) or EGF+TNF (500 nM of each) and incubated with cofactors (10 mM MnCl 2 0.5 mM FeSO 4 ) and unlabeled ATP (1 mM) for 30 min at 08C. The reactions were quenched and immunoprecipitated with anti-PTP1B (FG6-1G). Immune-complexes were immunoblotted with anti-phosphotyrosine. The migration of the 170 kDa EGFr band is shown. (C) Membrane fractions were treated as described in A (above) but incubated in the presence of unlabelled ATP. Fractions were held on ice, subjected to immunoprecipitation with A108, and proteins were resolved by SDS ± PAGE. After transfer to nitrocellulose, the membrane was immunoblotted with antibody against EGFr (top) or PTP1B (FG6-1G; bottom). The migration of 170 kDa EGFr (top) and 50 kDa PTP1B (bottom) are shown. Immunoglobulin heavy chain of A108 (Ig H) is also detected by anti-mouse secondary antibody its coprecipitation with PTP1B. Phosphoamino acid analysis of the 170 kDa 32 P-labeled protein immunoprecipitated with PTP1B antibody detected only radiolabeled phosphotyrosine which was absent in corresponding PTP1B immunoprecipitates of 32 Plabeled membrane proteins treated with EGF and TNF. Similar results were obtained when treated membrane fractions were incubated with unlabeled ATP, immunoprecipitated with anti-PTP1B and analysed by phosphotyrosine immunoblotting ( Figure  6B ). These in vitro studies provided preliminary evidence for an association between tyrosine phosphorylated EGFr and PTP1B in cellular membrane fractions derived from Sen cells. This association may be disrupted by TNF through a reduction in EGFr phosphotyrosine content. Additional support for this hypothesis was provided by EGFr immunoprecipitation studies from membrane-treated fractions. As shown in Figure 6C , EGF or TNF treatment did not aect recovery of EGFr but did alter its association with PTP1B. EGF induced tyrosine phosphorylation of EGFr ( Figure 6A ) and induced coprecipitation with PTP1B. Further, PTP1B association with EGFr was reduced when fractions were incubated with EGF in the presence of TNF. These results suggest that tyrosine phosphorylation of EGFr aects its association with PTP1B and this association may be modulated by TNF.
The possible involvement of PTP1B in the in vitro eects of TNF on EGFr tyrosine phosphorylation prompted and examination of the relative expression and activity of PTP1B in Sen and Res cells. Equal protein lysates immunoblotted with an antibody recognizing the C-terminus of PTP1B (Figure 7 ) revealed little distinction in PTP1B expression levels between cell types. However, immune-complex phosphatase assays of PTP1B activity (Figure 7 , bottom panel) estimated 2 ± 3-fold greater activity in Sen cellderived immune complexes when compared to Res cells. Immunoblot analysis of cell lysates with the antibody used to immunoprecipitate PTP1B for immune-complex phosphatase assays (FG6-1G) revealed the presence of additional PTP1B cross-reactive proteins which were detected in greater abundance in Sen cell lysates (Figure 7) . Similarly, immunoblots obtained with an antibody directed against the Nterminal domain of PTP1B (Figure 7 ) also detected dierential expression of PTP1B-like proteins in Sen and Res cell extracts. These results suggested that Cterminal alterations in PTP1B could be responsible for the appearance of PTP1B-like proteins in these cells.
To determine whether changes in PTP1B-related protein levels in ME-180 cells were speci®c for PTP1B and not representative of non-speci®c degradation of these proteins or post-lysis artifacts, Sen and Res cell extracts (prepared as in Figure 7 ) were immunoblotted with antibodies speci®c for additional PTPs including SH-PTP1, SH-PTP2 and T-cell PTP. As shown in 6 ) in 60 mm culture dishes were rinsed brie¯y with icecold PBS and lysed with the addition of 750 ml of SDS-sample buer pre-warmed to 608C. Fifty ml aliquots of lysate were heated to 958C, proteins were resolved by SDS ± PAGE (12.5% gel), transferred to nitrocellulose and immunoblotted with anti-PTP1B (FG6-1G) . The results are shown in the box at the right 8, right panel). These results suggested that distinctions in PTP1B-related protein levels between cell lines were not due to general changes in proteolysis of PTP proteins and were unlikely to represent post-lysis artifacts produced as a consequence of cell extraction.
Since the C-terminus of PTP1B has been shown to play a key role in its association with membranous organelles such as the endoplasmic reticulum (Frangioni et al., 1992) , cellular distribution of PTP1B-like proteins and the eects of TNF on their localization were examined in Sen and Res cells. Analysis of total protein extracts revealed that TNF caused only minor changes in the cellular content of PTP1B and PTP1B-like proteins in Sen or Res cells (Figure 9) . However, immunoblot analysis of detergent (particulate) and non-detergent (cytoplasmic) extracts derived from TNF-treated ME-180 cells suggested that TNF was able to mediate selective translocation or accumulation of the 42 kDa PTP1B-like protein in apoptotically responsive Sen cells but did not eect the level of the 36 kDa 1B-related protein (Figure 9 ). Importantly, TNF caused no change in the cytoplasmic level of either PTP1B-like protein in Res cells, suggesting a possible role for translocation or accumulation of speci®c PTP1B-related proteins (42 kDa) in TNF apoptotic action.
Discussion
Resistance to TNF-mediated apoptosis is common in tumor cells and may be mediated by a variety of mechanisms which disrupt TNF signaling or prevent cell death by increased expression of survival factors. Several reports have demonstrated that growth factors which activate receptor tyrosine kinases are able to delay or prevent apoptosis driven by TNF and other stimuli (Gardner and Johnson, 1996; Tilly et al., 1992; Garcia-Lloret et al., 1996; Sugarman et al., 1987; Shephard and Lewis, 1988; Nishikawa et al., 1994; Aggarwal et al., 1994; Wu et al., 1995) whereas ampli®ed expression of tyrosine kinases may constitutively activate survival signals and reduce the apoptotic actions of TNF (Wu et al., 1996; Gardner and Johnson, 1996; Garcia-Lloret et al., 1996; Sugarman et al., 1987; Hudziak et al., 1988; Lewis, 1988, Nishikawa et al., 1994; Aggarwal et al., 1994) . In earlier studies we presented evidence of a role for overexpression of EGFr in loss of TNF sensitivity in two squamous carcinoma cell lines and subsequently demonstrated that inhibition of EGFr enzymatic activity with tyrphostin increased sensitivity to TNF (Nishikawa et al., 1994; Donato et al., 1993; Perez and Donato, 1996) . In this report we describe the possible involvement of a protein tyrosine phosphatase in TNF action.
In this study, TNF was able to activate NF-kB and transiently stimulate JNK1 activity in both Sen and Res cells, demonstrating functional coupling of TNF receptors to downstream signaling cascades in either cell line (Hsu et al., 1995; Boldin et al., 1996; Muzio et al., 1996 . However, activation of these signaling processes alone did not correlate with the induction of apoptosis in these cell lines (Figure 1 ), in agreement with previous reports , and recent evidence suggesting that sustained activation of JNK1 is necessary to induce apoptosis in Jurkat and other tumor cell types (Chen et al., 1996a,b) . The transient activation of JNK1 in TNF-treated ME-180 cells suggests that it may play only a minor role in stimulating the apoptotic process. We have shown that PARP is cleaved following TNF incubation in Sen but not Res cells in agreement with recent reports (Donato and Perez, 1998) , and suggests that TNF resistance in these cells may be mediated by defects in caspase activation or by expression of survival factors (Fraser and Evans, 1996; Tewari and Dixit, 1995; Eastman, 1995) . Although enforced expression of bcl-2 and bcl-x can inhibit TNF-mediated ME-180 cell death (Jaattela et al., 1995) , we were unable to detect expression of these molecules in either Sen or Res ME-180 cells. Since EGF and insulin have been demonstrated to increase cell survival and alter TNF-induced cytotoxicity (Eastman, 1995; Merlo et al., 1995; Wu et al., 1996; Garcia-Lloret et al., 1996; Sugarman et al., 1987) , we investigated potential antagonism between TNF and survival pathways controlled by receptor tyrosine kinases.
In this study, we demonstrate that after a delayed onset, but prior to morphologic or biochemical evidence of apoptosis, TNF incubation caused a suppression of EGFr tyrosine phosphorylation (60% ) were treated with 1 nM TNF (for the interval noted) and lysates were prepared in lysis buer without detergent. After centrifugation, equal protein aliquots (20 mg) of the supernatant fraction, representing the cytosol, were resolved by SDS ± PAGE and immunoblotted with anti-PTP1B (FG6-1G) [right] . The pellet was solubilized with lysis buer and equal protein aliquots (5 mg), representing the particulate fraction, were resolved by SDS ± PAGE and immunoblotted as described above. The arrows depict 50, 42 and 36 kDa PTP1B protein migration in particulate and cytosolic extracts from Sen and Res cells of control levels) in Sen cells. Although TNF was able to activate TNF receptors in Res cells, it failed to induce apoptosis in these cells and had only minimal eects on EGFr tyrosine phosphorylation, suggesting distinctions in regulation of tyrosine phosphorylation between apoptotically sensitive and resistant ME-180 cells. Preliminary studies demonstrated that TNFmediated suppression of EGFr tyrosine phosphorylation was detectable 3 ± 4 h after TNF exposure and reached maximal suppression levels prior to the onset of apoptosis in Sen cells. TNF caused a sustained reduction in EGFr tyrosine phosphorylation without eecting EGFr protein levels, suggesting induction or activation of a tyrosine kinase inhibitor or phosphatase activity as possible mediators of this TNF eect. However, cycloheximide pretreatment, which augments TNF-mediated apoptosis (Wong et al., 1989) , did not block TNF-mediated EGFr suppression (data not shown) suggesting the involvement of a pre-existent or latent enzyme as a mediator of TNF eects on EGFr in ME-180 cells.
In vitro studies supported evidence for activation of a membrane-associated PTP by TNF in the presence of speci®c cofactors (Figures 3 ± 6 ). Due to the proposed involvement of oxygen radicals and oxidative stress in TNF action (Zimmerman et al., 1989; Schreck et al., 1991; Chang et al., 1992) , we examined a spectrum of cofactors which support oxidative processes and found and unusual requirement for iron in the in vitro actions of TNF. Low concentrations of transportable iron have been shown to be essential to the accumulation of oxygen radicals and cellular damage (Freeman and Crapo, 1982) and previous studies demonstrated that intracellular iron can modulate TNF cytotoxicity (Warren et al., 1993) . Ferrous and ferric ions have been shown to be essential to the production of oxygen radicals through propagation of the Fenton reaction (Korsmeyer, 1995; Freeman and Crapo, 1982) and inhibition of TNF-mediated cell death by a variety of antioxidants supports a role for oxidation in TNF signal transduction (Goossens et al., 1995; Zimmerman et al., 1989; Chang et al., 1992) . Cytochrome c, an iron-porphyrin containing protein, is released from the mitochondria of cells committed to undergo apoptosis, providing indirect evidence of a role for coordinated iron in the apoptotic signal (Krippner et al., 1996) . In our membrane phosphorylation studies, TNF mediated changes in EGFr dephosphorylation were only minimally detectable in the absence of iron but were signi®cantly enhanced in its presence while other divalent cations or metals (Ni as the ER and may be mediated by a process similar to that which promotes translocation of cytochrome C from the mitochondrial membrane of apoptotic cells. Studies with other mediators of apoptotic signaling (such as cytochrome C) or inhibitors of these processes may be useful in determining the precise role of iron in this response and the mechanism of PTP activation in vitro. The in vitro properties of the putative TNFactivated PTP and the recently described involvement of PTP1B in both EGF and insulin signaling pathways (Kenner et al., 1996; Flint et al., 1997; Bandyopadhyay et al., 1997; Liu and Cherno, 1997) , supported investigation of a role for PTP1B in TNF action. A protein:protein interaction between tyrosine phosphorylated EGFr and PTP1B was suggested by in vitro coprecipitation studies (Figure 6 ). This interaction appeared to be due to PTP1B anity for tyrosine phosphorylated EGFr as a substrate since activation of PTP activity by TNF decreased EGFr phosphotyrosine content (Figures 3 and 5 ) and disrupted the enzyme:substrate interaction between these proteins ( Figure 6 ). These results provide additional support for the utilization of tyrosine phosphorylated EGFr as a potential substrate for PTP1B but suggests that distinct compartmentalization of these transmembrane or membrane-associated proteins would preclude their interaction in intact cells except during nascent translation and processing of EGFr as recently described with`substrate trapping' PTP1B variant proteins (Flint et al., 1997) . However, expression of a truncated PTP1B protein, such that the hydrophobicmembrane anchoring domain is eliminated, may alter the cellular distribution and allow greater PTP1B interaction with tyrosine phosphoproteins, such as EGFr, or others highly expressed in epithelial tumors. In ME-180 cells the detergent extracted membrane fraction of both Sen and Res cells retained the majority of 50 kDa PTP1B but we could also detect the 50 kDa PTP1B protein in cell lysates prepared in the absence of detergent (Figure 9 ). This would suggest the existence of a pool of 50 kDa PTP1B which is not tightly associated with membranous components in ME-180 cells as previously described by others in cells modeling insulin resistance (Maegawa et al., 1995) . Other cell lines examined which express intrinsic TNF sensitivity also expressed a 42 kDa PTP1B-like protein (MCF-7, BT-20, MDA-361; data not shown) but we could not detect expression of the 50 kDa PTP1B in the cytosolic fraction of these cells, suggesting distinctions between ME-180 cells and other TNF sensitive cell lines. These results may suggest that the elements controlling expression or accumulation of the 42 kDa protein and those associated with the cytoplasmic localization of the 50 kDa protein are distinct and cell type speci®c. In this report, we provide evidence for both increased expression and tracking of PTP1B-like proteins in TNF-treated Sen cells. The role of translocation and expression of PTP1B-truncated proteins in TNF-mediated apoptosis is currently being examined.
Analysis of two PTPs involved in SH2 domaindependent signal transduction (SH-PTP1, SH-PTP2) and T-cell PTP revealed no distinctions in their level of expression between Sen and Res cells (Figure 8 ). In addition, we found no evidence for increased susceptibility of these proteins to degradation even though the epitopes recognized by some of these antibodies should allow detection of proteolytic products. However, immunoblots of Sen and Res cell extracts revealed distinctions in expression of lower molecular mass PTP1B-like proteins (550 kDa) cross-reactive with a catalytic domain directed antibody (FG6-1G) which were also detectable with antibodies recognizing the Nterminus of PTP1B (UBI). Microsequencing of these PTP1B-like proteins has con®rmed that these antibody cross-reactive proteins represent identical sequences found within the PTP1B protein (Donato and Graham, unpublished observation) . These results provide evidence for the derivation of these lower molecular mass forms of PTP1B by truncation within the C-terminal domain. These truncated proteins do not appear to be post-lysis artifacts since direct lysis of cells with SDS-sample buer did not signi®cantly alter the distinctions in PTP1B-like protein levels between cell lines. The precise mechanism of PTP1B truncation and cellular tracking in apoptotically responsive cells is unknown but may be related to processing pathways for PTP1B previously described (Frangioni et al., 1993) . Calcium-responsive proteases and other proteolytic enzymes were able to recognize and cleave PTP1B at its C-terminus and calpain inhibitors were able to prevent cleavage of PTP1B protein in platelets and activated T-cells (Frangioni et al., 1993; Rock et al., 1997) . However, while these inhibitors (calpeptins) were ineective in modifying the intrinsic level of PTP1B-like proteins in Sen cells, other agents which alter Ca 2+ stores (A23187, thapsigargin) eect PTP1B-like proteins in Sen cells (Donato, et al., manuscript in preparation) demonstrating that Ca 2+¯u x can eect PTP1B-like protein expression in Sen cells but its mechanism of action may be distinct from that which controls intrinsic PTP1B-like protein levels in ME-180 cells.
TNF caused an increase in the cytoplasmic 42 kDa form of PTP1B but had no eect on the cytoplasmic or cellular level of the 36 kDa protein. This may be related to the association of the 36 kDa PTP1B protein with SH3 domains of membrane-localized adaptor proteins . This distinct compartmentalization of the 36 kDa protein may alter its participation in TNF-mediated translocation and it may mediate other activities independent of those associated with TNF (Liu et al., 1998) . The dierential expression and translocation of the 42 kDa protein in ME-180 cell variants and other cell lines expressing intrinsic sensitivity to TNF strongly suggests a possible role for this protein in de®ning a TNF sensitive phenotype. One possible mechanism may involve the uncoupling of tyrosine phosphorylated receptor signaling events from activation of down stream cell growth or survival pathways. However, PTP1B-like truncated proteins may also associate with other signaling proteins in a phosphotyrosine independent fashion and mediate changes in other signaling events (Liu et al., , 1998 Rock et al., 1997) . Analysis of the preferred substrate interaction of the 50, 42 and 36 kDa proteins may provide additional information about the role of these molecules in signal transduction and apoptosis.
In this report we present evidence for TNF-mediated tyrosine dephosphorylation of EGFr in ME-180 cells and suggest that at least in part, these eects may be mediated by activation of a tyrosine phosphatase with properties similar to that of PTP1B. We also present evidence for dierential expression and cytoplasmic localization of PTP1B-like proteins in apoptotically sensitive and resistant ME-180 cells and suggest that TNF may alter cellular distribution of these proteins. Detailed analysis of the intrinsic activities responsible for regulation and production of PTP1B-like proteins and the interaction of these proteins with tyrosine phosphoproteins (i.e. EGFr) may provide additional support of a role and mechanism for tyrosine phosphomodulation in TNF-mediated apoptosis.
Materials and methods
Cell lines ME-180 clonal variant cell lines expressing sensitivity or resistance to TNF have previously been described and characterized (Donato et al., 1993; Perez and Donato, 1996; Donato and Perez, 1998) . All cell lines were maintained in minimal essential media supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA). Apoptotic sensitivity to TNF was determined by three techniques: (1) crystal violet staining of cells following TNF exposure for 24 ± 72 h in 96-well plates; (2) detection of a PARP cleavage product (85 kDa) by immunoblot analysis following TNF incubation and (3) monitoring DNA nucleosomal fragmentation following TNF treatment as previously described (Donato et al., 1993; Donato and Perez, 1998) .
Antibodies and reagents
Antibodies used in these studies include; EGFr monoclonal antibody A108 for immunoprecipitation [from RorerRhone-Poulonc (King of Prussia, PA, USA)] and EGFr antibody for immunoblotting [Transduction Laboratories, (Lexington, KY, USA)]. Monoclonal antibodies against various PTP1B epitopes including the catalytic (FG6-1G) and C-terminal (AE4-2J) domains were purchased from Oncogene Sciences (Cambridge, MA, USA). Polyclonal antibody against the N-terminus of PTP1B was obtained from UBI (Lake Placid, NY, USA). Antibodies against other PTPs include T-cell PTP (Oncogene Sciences), SH-PTP1 and SH-PTP2 (Transduction Laboratories). Monoclonal antibody 4G10 against phosphotyrosine was purchased from UBI. Pansorbin was obtained from CalBiochem (La Jolla, CA, USA). Antibody against PARP was purchased from Pharmingen (San Diego, CA, USA).
Human recombinant TNF was provided by Genentech Corp. (S. San Francisco, CA, USA) and human recombinant EGF was purchased from R&D Systems (Minneapolis, MN, USA). The peptides DADEYLIPQQG (Y992) and RRDA-DEYLIPQQC (RY992), utilized to assay tyrosine phosphatase activity in cell lysates (Milarski et al., 1993) were synthesized by solid phase chemistry (fMOC) as previously described (Atherton and Sheppard, 1989) and were generous gifts from Dr John McMurray, Department of Neurooncology, MD Anderson Cancer Center.
Preparation of cell lysates, membranes and cytosol
Total cell lysates were prepared as previously described (Donato et al., 1993; Perez and Donato, 1996) . Brie¯y, cells were rinsed with ice-cold PBS, collected by centrifugation and lysed in lysis buer consisting of 20 mM Naphosphate, pH 7.4, 1% Triton X-100, 150 mM NaCl, 5 mM EDTA, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mM PMSF, 50 mM NaF and 2.5 mM Na-vanadate. Cell suspensions were brie¯y sonicated on ice (2 s, low power setting, Kontes micro-cell disruptor) and lysates clari®ed by ultracentrifugation (100 000 g, 60 min, 48C). Equal protein aliquots were resolved by SDS ± PAGE, transferred to nitrocellulose membranes, immunoblotted with primary antibody, detected with HRP-conjugated secondary antibody (BioRad Laboratories) and ECL reagent (Amersham Corp., Rockford, II, USA).
Cytosolic extracts were prepared by sonication (as described above) in lysis buer without Triton X-100. Following centrifugation at 100 000 g (60 min, 48C), the supernatant fraction was used as the source of cytosolic protein. After removal of all the supernatant, the pellet was extracted with normal lysis buer and used as the source of particulate protein.
The cellular membrane fraction (high and low density) was isolated by sucrose density gradient centrifugation as previously described (Frangioni et al., 1992) . Cells were grown to con¯uence in 150 mm culture plates and equilibrated in serum-free media (overnight) prior to membrane preparation. Monolayers were placed on ice and rinsed three times with ice-cold PBS containing 2.5 mM EDTA and collected by releasing with a cell scraper and centrifugation (1000 g, 10 min, 48C). The cell pellet was resuspended in hypotonic buer consisting of 20 mM HEPES, pH 7.4, 2.5 mM EDTA, 4 mM iodoacetic acid, 10 mg/ml leupeptin and 10 mg/ml aprotinin. After 15 min on ice, cells were dounce homogenized (50 strokes) and made 0.25 M in sucrose concentration prior to centrifugation at 2000 g at 48C for 10 min. The supernatant fraction (containing cellular membranes) was retained and membranes pelleted by ultracentrifugation (100 000 g, 60 min, 48C). The membranes were resuspended in 20 mM HEPES, pH 7.4, containing 5 mM MgCl 2 and repelleted. Pelleted membranes were once again resuspended in 20 mM HEPES, pH 7.4, and collected by centrifugation prior to ®nal resuspension in 20 mM HEPES, pH 7.4 at a protein concentration of 1.5 ± 2 mg/ml. This fraction was utilized as a source of cellular membranes and retained 480% of the transmembrane EGFr protein when compared to total cell lysates (data not shown).
Assay of membrane phosphatase activity
Membrane-associated phosphatase activity was assessed by two methods. First, the eect of cytokine and growth factor treatment on total membrane protein phosphorylation was assessed by incubation of 50 mg of membrane protein with TNF or EGF (or both), cofactors [MnCl 2 (10 mM), FeSO 4 (0.5 mM)] and [ 32 P]ATP (20 mCi) in a total volume of 100 ml (20 mM HEPES, pH 7.4). After incubation for 30 min at 0 ± 48C, the reaction was quenched by heated to 1008C and phosphoproteins were resolved by SDS ± PAGE. Phosphorylation was detected by autoradiography. In some experiments, 1 mM Na-vanadate was added prior to the addition of ATP. Tyrosine-speci®c dephosphorylation was determined by incubation of the membrane preparations with unlabeled ATP (1 mM) and tyrosine phosphorylation of membrane proteins was determined by phosphotyrosine immunoblotting of SDS ± PAGE resolved proteins.
The second assay utilized a 32 P-labeled phosphopeptide mimicking an autophosphorylation site (Y992) on EGFr as a tyrosine phosphatase substrate (Milarski et al., 1993) . One hundred mg of Y992 peptide (described above) was incubated with 200 mg of cellular membranes prepared from A431 cells (Donato et al., 1992) in 20 mM HEPES buer, pH 7.4 containing 10 mM MnCl 2 0.5 mM Na-vanadate and 100 mCi [ 32 P]ATP for 16 h at 48C. The reaction was quenched with 20 mM EDTA and membranes repelleted by centrifugation. The peptide was denatured (1% tri¯uoroacetic acid) and resolved by reversephase HPLC (C 18 column equilibrated in 0.1% TFA) and eluted (1 ml/min) with a linear gradient of acetonitrile. Radioactive fractions were pooled, concentrated on a Speed vac concentrator and rechromatographed as described above. The ®nal product was lyophilized and resuspended in 20 mM HEPES buer, pH 7.4 (speci®c activity *0.65 mCi/mg). To assess phosphatase activity in membrane preparations, the cellular membrane fraction was prepared as described above and treated with cytokines and cofactors before the addition of phosphopeptide (0.5610 6 c.p.m.) to the incubation mixture. After 30 min, the reactions were terminated with the addition of EDTA and the membranes pelleted by centrifugation. The supernatant was removed and aliquots (10 ml) were acidi®ed (with 1% TFA) and resolved by HPLC (0.1% TFA with a 0 ± 45% acetonitrile linear gradient at 1 ml/min from 5 to 65 min) and radioactivity in fractions was determined by Cerenkov counting. Radioactivity in fractions 6 ± 8 (representing free 32 P) was utilized as a relative measure of phosphatase activity.
Immune-complex tyrosine phosphatase assay
The RY992 peptide was synthesized, radiolabeled and puri®ed as described above and utilized as a substrate for PTP1B enzymatic assays as previously described (Frangioni et al., 1993) . Brie¯y, 10 mg of cell lysate was incubated with 0.5 mg of anti-PTP1B (FG6-1G) antibody (or anti-EGFr A108 as a control) and immunoprecipitated with Pansorbin. After washing three times in lysis buer, immune-complexes were resuspended in phosphatase buer (25 mM HEPES, pH 7.4, 10 mM DTT), incubated at 308C for 0 ± 30 min in the presence of 32 P-labeled RY992 and reactions quenched with the addition of 1 N HC1. Aliquots were spotted onto P81 phosphocellulose paper, washed in 75 mM phosphoric acid and radioactivity was measured by scintillation counting. Loss of 32 P from radiolabeled phosphopeptide was utilized as a comparative measure of PTP1B activity in cell lysates.
Immunoprecipitation of EGFr from total cell lysates and solubilized membrane preparations
EGFr was immunoprecipitated from cell lysates (prepared in 1 ml of lysis buer as described above) by the sequential addition of 2 mg of A108 monoclonal antibody and Pansorbin (Perez and Donato, 1996) . Immune-complexes were washed, disrupted with SDS-sample buer and resolved by SDS ± PAGE. Proteins were transferred to nitrocellulose and immunoblotted with antibody against EGFr (Transduction Laboratories Lexington, KY, USA) or phosphotyrosine (4G10) and detected with 125 I-labeled secondary antibody (Amersham) or peroxidase-conjugated secondary antibody (Bio-Rad) and ECL detection reagent. Blots were quantitated by counting gel slice radioactivity or densitometry. For immunoprecipitation of EGFr from cellular membrane preparations, after incubation with ATP, the reactions were quenched by the addition of EDTA (20 mM) and samples were diluted to 1 ml with lysis buer. The immunoprecipitation and washing of immunecomplexes were carried out as described above. In some experiments EGFr phosphorylation was performed in the presence of unlabeled ATP and phosphotyrosine detected by immunobloting. Phosphoamino acid analysis of gel bands containing 32 P-labeled protein were hydrolyzed for 1 h in 5.7 M HCl (Pierce Chem. Co.) according to a procedure previously described (Cooper et al., 1983) . After lyophilization of the hydrozylate, the sample was resolved by thin-layer cellulose electrophoresis at pH 3.5.
Nuclear preparations and electrophoretic mobility shift assays
Cells were treated with TNF for the intervals indicated and nuclear extracts were prepared as described by others (Schreiber et al., 1989) . Following incubation of 5 mg of nuclear extract with 16 fmol of 32 P-labeled double-stranded NF-kB oligonucleotide (Nabel and Baltimore, 1987) for 20 min at 378C in a buer consisting of 25 mM HEPES, pH 7.9, 0.5 mM EDTA, 0.5 mM DTT, 1% NP-40, 5% glycerol, 50 mM NaCl and containing 2 mg poly(dI-dC), oligonucleotide and DNA-protein complexes were resolved on native polyacrylamide (7.5%) gels and detected by autoradiography. Non-speci®c DNA-protein binding complexes were detected by including a 100-fold molar excess of unlabeled oligomer in the incubation mixture.
JNK activity assay
Cell lysates were prepared from control or TNF treated cells and sequentially incubated with antibody directed against the C-terminus of JNK1 (Santa Cruz Biologicals) and Pansorbin. Immune-complexes were washed with lysis buer, resuspended in 50 mM HEPES, pH 7.4, containing 10 mM MgCl 2 and incubated with 10 mCi 32 P-ATP in the presence of 5 mg of GST-Jun (Santa Cruz Biologicals) for 15 min at 308C. The reactions were terminated with the addition of SDS-sample buer, proteins were resolved by SDS ± PAGE and GST-Jun phosphorylation detected by autoradiography.
Abbreviations EGF, epidermal growth factor; TNF, tumor necrosis factor; PTP, protein tyrosine phosphatase.
